Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.

  • Posted by: Biocon Biologics

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

  • Posted by: Biocon Biologics

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

  • Posted by: Biocon Biologics

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

  • Posted by: Biocon Biologics

Biocon Academy Conducts its 9th Graduation Day

  • Posted by: Biocon Biologics

Biocon Foundation Marks 20 Years of Transforming Lives Through Impactful Social Initiatives

  • Posted by: Biocon Biologics

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States

  • Posted by: Biocon Biologics

European Commission Approves Biocon Biologics’ Ustekinumab Biosimilar

  • Posted by: Biocon Biologics

Biocon Foundation Dedicates Metro Pillars Public Art Project to ‘Everyday Champions’ of Bengaluru

  • Posted by: Biocon Biologics

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr

  • Posted by: Biocon Biologics
Share
buy twitter followers - matadorbet güncel adres - onwin - onwin güncel adres - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler -

groepenkast

- takipcimx 1000 - buy facebook followers